The Amazingly Stupid Things Smartphone Users Do While Driving
If you’re reading this while driving, put your phone down right now. This article — as engrossing as it is — will still be here when you reach your destination.
We provide that friendly bit of advice because, as The New York Times reported this morning, a whole bunch of motorists are occupying themselves with their smartphones — and distracting themselves from the road — in ways that go way beyond talking and texting, according to a new survey conducted by Braun Research for AT&T.
The pollsters surveyed 2,067 smartphone users who drive daily, and their findings should be frightening to anyone on the roads. More than six in 10 smartphone users surveyed say they text while driving. It gets scarier: Nearly 40 percent of smartphone users admit to checking in on social media while driving, with 27 percent admitting to using Facebook and another 14 percent saying they use Twitter and Instagram while behind the wheel. Of users who cop to posting on Twitter while driving, 30 percent say they do it “all the time.” Given those figures, it’s amazing that #TwitterAccident isn’t always trending.
Related: Here's How Much Likelier You Are to Be Killed in a Car Than on Amtrak
Some other troubling stats from the survey: 17 percent snap selfies or other pictures when in the driver’s seat and 12 percent shoot videos — with 27 percent of those videographers thinking they can do so safely. Astoundingly, 10 percent of drivers say they video chat while on the roads.
AT&T says it will expand its It Can Wait public service campaign about the dangers of distracted driving, which launched in 2010, to focus on hazards beyond just texting. But as Matt Richtel of the Times points out, the AT&T campaign and other efforts like it face a stiff challenge in trying to counter the social pressures and strongly ingrained habits that keep people constantly checking their phones.
Tough laws and widespread educational efforts have been effective at reducing drunk driving and encouraging use of seat belts. But we still have a way to go in getting drivers to understand that “mobile” doesn’t mean when you’re behind the wheel. Right now, 46 states and the District of Columbia have outlawed texting while driving. As you can see above, that hasn't helped much yet. Smartphone users still need to be convinced of the danger they pose — or face — if they use their devices while driving.
As Lori Lee, AT&T’s global marketing officer, put it: “For the sake of you and those around you, please keep your eyes on the road, not on your phone.”
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.